Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprotinin for transfusion reduction in bladder cancer patients undergoing radical or total cystectomy
2005-004055-35Phase 3Terminated
- Sponsor
- Bayer
- Start
- Nov 2005
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bladder cancer comparing Trasylol with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Primary objective. Started Nov 2005; status: terminated.
02
Drugs
aprotinin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2005-004055-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004055-35.